Pfizer Executives Elaborate On Payer Biosimilar Contracting Goals, Challenges
Pfizer Executives Elaborate On Payer Biosimilar Contracting Goals, Challenges

At a recent press conference, Pfizer executives shared a few key updates related to Inflectra’s uptake and the ongoing efforts to work with commercial payers. These updates not only shed more light on Inflectra’s market journey, but also reassured me that progress is being made — even though it’s not regularly broadcast in headlines.

  • 3 Biosimilar Barriers In Community Clinics
    3 Biosimilar Barriers In Community Clinics

    In the first of this two-part article, McKesson experts share insights on two biosimilar barriers they’ve noticed in community clinics and highlight their takeaways from infliximab’s and filgrastim’s experiences tackling these barriers.

  • Partnering With Insurers To Improve Biosimilar Access In The U.S.
    Partnering With Insurers To Improve Biosimilar Access In The U.S.

    Drug developers have found a powerful ally in their campaign to advance biosimilar adoption in the U.S. — the nation’s health insurance providers. Insurers are keen to drive down the price of reference biologics, and they view biosimilars as an important way to accomplish that goal.

  • 90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?
    90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?

    This review sought to answer two questions which have been plaguing the biosimilar industry since day one: will biosimilar switching have any impact on safety, and will biosimilars be the harbingers of increased immunogenicity? And it has provided us with far more than just answers to these questions.

  • Unlocking The Potential Of Real-World Data: Tapping Into Today’s Data To Improve Healthcare Tomorrow
    Unlocking The Potential Of Real-World Data: Tapping Into Today’s Data To Improve Healthcare Tomorrow

    Healthcare is undergoing a shift in how key stakeholders approach and evaluate patient data -- driven by growing access to and general use of real-world data, such as de-identified patient data collected and analyzed from registries, electronic health records, wearable devices, and administrative and healthcare claims databases. This type of data is increasingly being utilized by industry representatives to help inform device development, health system operations, formularies and resulting coverage, and patient care decisions.

  • Electrospinning & The Future Of Continuous Pharmaceutical Manufacturing
    Electrospinning & The Future Of Continuous Pharmaceutical Manufacturing

    Blair Brettmann, Ph.D., assistant professor in Georgia Tech’s School of Materials Science and Engineering, discusses the current state of continuous manufacturing in the pharmaceutical industry, her group’s research into electrospinning and other novel approaches, and how to overcome the challenges to further adoption of continuous processes.

  • Does The U.S. Biosimilar Space Have A Case Of “Progressophobia?”
    Does The U.S. Biosimilar Space Have A Case Of “Progressophobia?”

    A prediction that a failure of the U.S. biosimilars market could lead to the end of the global biosimilars market begs the question of how we evaluate progress, as well as how such a prediction could be avoided.

  • Could This Practice Increase Biosimilar Use In The U.S.?
    Could This Practice Increase Biosimilar Use In The U.S.?

    What could a country like the U.S. and big payers like the Aetna’s, UnitedHealthcare’s, or even the PBMs like CVS learn from what other countries have done to garner savings for their healthcare systems and potentially reduce costs for patients?

  • How The EU Influences U.S. On Biosimilar Interchangeability & Other Policies
    How The EU Influences U.S. On Biosimilar Interchangeability & Other Policies

    This articles highlights the meaning of the NOR-SWITCH trial results and how the EU’s view of biosimilars as therapeutic alternatives, rather than generics, has influenced U.S. policy.

  • A Tale Of Two Annexes: Analyzing EMA's Revisions To Annex 1 & 13
    A Tale Of Two Annexes: Analyzing EMA's Revisions To Annex 1 & 13

    A Tale of Two Cities by Charles Dickens opens with the famous line, “It was the best of times, it was the worst of times.” This parallels two annexes recently updated by the European Medicines Agency (EMA) — one avoids the turmoil (Annex 13), while the other undergoes major upheaval (Annex 1).

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

More From Biosimilar...

TRAINING COURSES

Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum April 23 - 23, 2018
April 23, 2018 | 1:00 - 2:30 PM EDT)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Instructional Design for GMP Training – Improve Effectiveness and Measurability April 24, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Measuring CAPA Effectiveness: Critical Tips in Getting the Right CAPA and Showing It Works April 25 - 25, 2018
2pm-3:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Executing Proper Event Investigations: Critical Steps In Ensuring Compliant Corrective Actions May 2 - 2, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $199 - Includes Bonus Handouts!
Effective Batch Record Review - Getting It Right The First Time May 7 - 7, 2018
RECORDING, Online Training)
Duration:  90 minutes
Price:  $299 - Includes Bonus Handouts!
Biocontainment For Manufacturing: Understanding The Risks, Guidance, and Design Requirements May 8 - 8, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
FDA Guidance for Industry “Process Validation: General Principles & Practices” – Whatever Happened to IQ, OQ, PQ? May 16 - 16, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
The Core Competencies of a World-Class Medical Affairs Team May 17 - 17, 2018
1pm-2:00pm EDT, Online Training)
Price:  $199 - Includes Bonus Handouts!
The EU General Data Protection Regulation (GDPR): What US Companies Need To Know To Comply May 22 - 22, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
World Biosimilar Congress USA 2018 May 23 - 24, 2018
San Diego, CA, CA)
More Upcoming Courses
Anna Rose Welch article header

 EVENTS

Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum April 23 - 23, 2018
April 23, 2018 | 1:00 - 2:30 PM EDT)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Instructional Design for GMP Training – Improve Effectiveness and Measurability April 24, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Measuring CAPA Effectiveness: Critical Tips in Getting the Right CAPA and Showing It Works April 25 - 25, 2018
2pm-3:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Executing Proper Event Investigations: Critical Steps In Ensuring Compliant Corrective Actions May 2 - 2, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $199 - Includes Bonus Handouts!
Effective Batch Record Review - Getting It Right The First Time May 7 - 7, 2018
RECORDING, Online Training)
Duration:  90 minutes
Price:  $299 - Includes Bonus Handouts!

LIFE SCIENCE INDUSTRY EVENTS

Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum April 23 - 23, 2018
April 23, 2018 | 1:00 - 2:30 PM EDT
Effective Batch Record Review - Getting It Right The First Time May 7 - 7, 2018
RECORDING, Online Training
More Industry Events

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.